The estimated Net Worth of Moria Kwiat is at least $430 millier dollars as of 8 April 2019. Moria Kwiat owns over 28,571 units of Pluri Inc stock worth over $373,571 and over the last 11 years he sold PSTI stock worth over $56,375. In addition, he makes $0 as Independent Director at Pluri Inc.
Sign up
Moria Kwiat PSTI stock SEC Form 4 insiders trading
Moria has made over 2 trades of the Pluri Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 28,571 units of PSTI stock worth $20,000 on 8 April 2019.
The largest trade he's ever made was buying 28,571 units of Pluri Inc stock on 8 April 2019 worth over $20,000. On average, Moria trades about 3,734 units every 173 days since 2013. As of 8 April 2019 he still owns at least 373,571 units of Pluri Inc stock.
You can see the complete history of Moria Kwiat stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Moria Kwiat biography
Dr. Moria Kwiat serves as Independent Director of the Company. Dr. Kwiat is an analyst at aMoon, a leading Israeli life sciences venture fund. Previously she was a consultant and analyst at Frost & Sullivan, producing equity research for public companies in the healthcare domain. Dr. Kwiat has a broad academic background and scientific experience in inter-disciplinary fields, with specific expertise in the interface between the biology and materials fields. She is the co-author of multiple scientific papers. Dr. Kwiat holds a Post-Doctoral degree in nanotechnology and material sciences, a Ph.D. in Chemistry and a M.Sc. and B.Sc. in Biotechnology, from Tel Aviv University.
How old is Moria Kwiat?
Moria Kwiat is 40, he's been the Independent Director of Pluri Inc since 2020. There are 6 older and 1 younger executives at Pluri Inc. The oldest executive at Pluri Inc is Mark Germain, 69, who is the Independent Director.
What's Moria Kwiat's mailing address?
Moria's mailing address filed with the SEC is MATAM PARK, BUILDING #5, , HAIFA, L3, 3508409.
Insiders trading at Pluri Inc
Over the last 17 years, insiders at Pluri Inc have traded over $7,081,854 worth of Pluri Inc stock and bought 2,345,914 units worth $14,327,834 . The most active insiders traders include Wolf Capital Limited Part..., Zami Aberman et Israel Ben Yoram. On average, Pluri Inc executives and independent directors trade stock every 64 days with the average trade being worth of $54,123. The most recent stock trade was executed by Zami Aberman on 10 February 2022, trading 80,616 units of PSTI stock currently worth $145,109.
What does Pluri Inc do?
Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a
What does Pluri Inc's logo look like?
Complete history of Moria Kwiat stock trades at Pluri Inc
Pluri Inc executives and stock owners
Pluri Inc executives and other stock owners filed with the SEC include:
-
Yaacov Yanay,
Pres, CEO & Director -
Zalman Aberman,
Executive Chairman of the Board -
Yaky Yanay,
President, Chief Executive Officer, Director -
Chen Franco-Yehuda,
Chief Financial Officer, Treasurer, Secretary -
Dana Rubin,
Director of Investor Relations -
Moria Kwiat,
Independent Director -
Mark Germain,
Independent Director -
Isaac Braun,
Independent Director -
Doron Shorrer,
Lead Independent Director -
Dr. Nitsan Halevy M.D.,
Chief Medical Officer -
Efrat Livne-Hadass,
VP of HR -
Lior Raviv,
Chief Technology Officer -
Israel Ben Yoram,
Director -
Nachum Rosman,
Director -
Hava Meretzki,
Director -
Erez Egozi,
Chief Financial Officer -
Shai Pines,
Director -
Boaz Gur Lavie,
CFO -
Wolf Capital Limited Part...,
10% owner -
Maital Shemesh Rasmussen,
Director -
Rami Avraham Levi,
Director -
Pinhas Doron Birger,
Director -
Varda Shalev,
Director -
Zami Aberman,
Director